PhaseBio Pharmaceuticals Consolidated Net Income/Loss

Consolidated Net Income/Loss of PHAS for past 10 years: annual, quarterly and twelve month trailing (TTM) including Consolidated Net Income/Loss growth rates and interactive chart.


Highlights and Quick Summary

  • Consolidated Net Income/Loss for the quarter ending June 29, 2021 was $-28.7 Million (a 4.83% increase compared to previous quarter)
  • Year-over-year quarterly Consolidated Net Income/Loss increased by 14.06%
  • Annual Consolidated Net Income/Loss for 2020 was $-98.6 Million (a 151.14% increase from previous year)
  • Annual Consolidated Net Income/Loss for 2019 was $-39.2 Million (a 64.59% increase from previous year)
  • Annual Consolidated Net Income/Loss for 2018 was $-23.8 Million (a 132.71% increase from previous year)
  • Twelve month Consolidated Net Income/Loss ending June 29, 2021 was $-112 Million (a 0.48% increase compared to previous quarter)
  • Twelve month trailing Consolidated Net Income/Loss increased by 40.28% year-over-year
Trailing Consolidated Net Income/Loss for the last four month:
29 Jun '21 30 Mar '21 30 Dec '20 29 Sep '20
$-112 Million $-111 Million $-98.6 Million $-79.5 Million
Visit stockrow.com/PHAS for comprehensive keystats, realtime prices, income statement, balance sheet, cash flow statement with 10 years of data, and state-of-the-art screener.

Historical Consolidated Net Income/Loss of PhaseBio Pharmaceuticals

Most recent Consolidated Net Income/Lossof PHAS including historical data for past 10 years.

Interactive Chart of Consolidated Net Income/Loss of PhaseBio Pharmaceuticals

PhaseBio Pharmaceuticals Consolidated Net Income/Loss for the past 10 Years (both Annual and Quarterly)

(All values are in $ million)

Year Q1 Q2 Q3 Q4 Fiscal Year
2021 $-28.68 $-27.36
2020 $-30.38 $-25.14 $-28.14 $-14.91 $-98.57
2019 $-11.33 $-11.39 $-9.23 $-7.29 $-39.25
2018 $-4.87 $-7.9 $-6.67 $-4.4 $-23.85
2017 $-2.56 $-10.25
2016 $-9.22

Business Profile of PhaseBio Pharmaceuticals

Sector: Healthcare
Industry: Biotechnology
PhaseBio Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel for cardiopulmonary diseases. Its lead product candidate is bentracimab (PB2452), a reversal agent for the antiplatelet drug ticagrelor that is in Phase III clinical trial for patients with uncontrolled major or life-threatening bleeding events or in patients requiring urgent or emergency surgery. The company is also developing PB1046, a vasoactive intestinal peptide analogue that is in Phase IIb clinical trial for the treatment of pulmonary arterial hypertension; and PB6440 for the treatment of resistant hypertension. The company has a co-development agreement with SFJ Pharmaceuticals X, Ltd. to develop PB2452, a reversal agent for the antiplatelet drug ticagrelor. PhaseBio Pharmaceuticals, Inc. was incorporated in 2002 and is based in Malvern, Pennsylvania.